DreaMed Diabetes achieves unprecedented validation of Advisor Pro, its AI-based insulin recommendations technology
PETAH TIKVA, Israel, Sept. 16, 2019 /PRNewswire/ — DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that it has received U.S Food and Drug Administration (FDA) clearance as well as CE Mark for DreaMed Advisor Pro, an artificial intelligence (AI)-based insulin dosing decision support software, for use by people with Type 1 diabetes (T1D) using insulin pump therapy with continuous glucose sensors and/or blood glucose meters (BGMs). This clinical and technological advance leverages the power of artificial intelligence to optimize insulin administration in a streamlined and cost-effective manner.
DreaMed Advisor Pro previously received a CE Mark and was cleared by the FDA for people with T1D using an insulin pump and a continuous glucose monitor (CGM) and has already been incorporated as a decision support system for optimizing insulin pump therapy in several US clinics as part of the quality improvement collaboration of the T1D exchange registry.
More here –> Yahoo Finance